Active	Status	Sponsor type	Region	Phase	Filter
3 Active 4 Inactive 7 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Kappaproct (cobitolimod) / InDex Pharma, Viatris
CONCLUDE, NCT04985968 / 2021-002549-13: The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis Jun 2023 - Dec 2023: Safety and efficacy data from CONCLUDE trial for ulcerative colitis	Terminated	3	171	Europe, Canada, US, RoW	Cobitolimod 250 mg, Kappaproct, Cobitolimod 500 mg, Placebo	InDex Pharmaceuticals	Ulcerative Colitis	12/23	12/23
2021-003023-14: Pharmacokinetics of Cobitolimod Enemas in Participants with active Ulcerative Colitis	Not yet recruiting	1/2	20	Europe	DIMS0150, Rectal solution	InDex Pharmaceuticals AB, InDex Pharmaceuticals AB	Moderate to Severe Active Ulcerative Colitis, Moderate to Severe Active Ulcerative Colitis, Diseases [C] - Digestive System Diseases [C06]
NCT05404074: Pharmacokinetics of Cobitolimod Enemas in Participants With Active Ulcerative Colitis	Recruiting	1	6	Europe	Cobitolimod 500mg, Kappaproct	InDex Pharmaceuticals	Ulcerative Colitis	10/22	10/22